In addition to the already existing clinical development centered around rare diseases, development of oligonucleotide therapeutics for common diseases and intractable diseases such as cancer is ...

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymat ...

DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030" report has been added to ...

With oligonucleotides on the rise to treat rare diseases and cancers, Japanese manufacturer Nitto Denko is laying big plans. Nitto will plug a whopping 25 billion yen ($225.93 million) into its ...

Enzymatic synthesis may be more sustainable for large-scale oligonucleotide manufacturing than traditional solid-phase techniques.

Opportunities in the peptide and oligonucleotide CDMO market include growing demand for personalized medicine, increased ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights the global oligonucleotide synthesis market is estimated to be valued at US$ 2,874.1 Million in 2020, and is expected to exhibit a CAGR ...

Oligonucleotide therapies offer a targeted approach to modulating gene expression, splicing, and protein production. By selectively manipulating specific molecular processes, these therapies hold the ...

The successful application of RNA therapies to rare diseases, neurological disorders, and other conditions as well as the plethora of biopharmaceutical companies developing new RNA-based therapeutics, ...

MILFORD, Mass., Nov. 7, 2017 /PRNewswire/ -- Nitto Avecia Inc. (Avecia) announced today the successful completion of the first synthesis runs at the 1.6 Mol scale which is believed to be the largest ...

Scientists have developed a new approach to produce life-saving oligonucleotide therapeutics on a large scale, in high purity, and with minimal environmental impacts. Scientists have developed a new ...

Agilent Technologies has opened a 12,500 m 2 oligonucleotide production plant in Frederick, Colorado, to meet growing demand for the RNA and DNA molecules that biotech firms are developing as ...